Clinical Features of 73 Patients with Lymphoma
| Parameters | No. of patients |
|---|---|
| Sex | |
| Male | 37 (50.68%) |
| Female | 36 (49.32%) |
| Age | |
| >60 y | 26 (35.62%) |
| ≤60 y | 47 (64.38%) |
| Treatment type | |
| Initial assessment | 48 (65.75%) |
| Progressed | 17 (23.29%) |
| Relapsed | 8 (10.96%) |
| Lesion distribution | |
| Nodal only | 15 (20.55%) |
| Extranodal, primary | 19 (26.03%) |
| Both | 39 (53.42%) |
| Histologic subtype | |
| HL | 11 (15.07%) |
| NHL | 62 (84.93%) |
| DLBCL | 34 (46.57%) |
| ENKTCL | 5 (6.85%) |
| AITL | 4 (5.48%) |
| PMBL | 2 (2.74%) |
| BL | 1(1.37%) |
| MCL | 1 (1.37%) |
| B-LBL | 1 (1.37%) |
| C-ALCL | 1 (1.37%) |
| CD8+ AECTCL | 1 (1.37%) |
| FL | 9 (12.33%) |
| MALT lymphoma | 2 (2.74%) |
| CLL/SLL | 1 (1.37%) |
ENKTCL = extranodal natural killer/T-cell lymphoma; AITL = angioimmunoblastic T-cell lymphoma; PMBL = primary mediastinal large BCL; BL = Burkitt lymphoma; MCL = mantle cell lymphoma; B-LBL - B lymphoblastic leukemia/lymphoma; C-ALCL = primary cutaneous anaplastic large-cell lymphoma; CD8+ AECTCL = cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma; FL= follicular lymphoma; CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma.